Gerard Silvestri to Biomarkers, Tumor
This is a "connection" page, showing publications Gerard Silvestri has written about Biomarkers, Tumor.
Connection Strength
2.224
-
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2022 01; 11(2):530-538.
Score: 0.606
-
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer. Chest. 2021 12; 160(6):2293-2303.
Score: 0.586
-
Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons. Clin Lung Cancer. 2020 03; 21(2):e89-e98.
Score: 0.509
-
"Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study". BMC Cancer. 2021 Apr 01; 21(1):352.
Score: 0.144
-
Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from?the National Lung Cancer Roundtable. J Thorac Oncol. 2019 03; 14(3):338-342.
Score: 0.124
-
Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med. 2017 10 01; 196(7):e15-e29.
Score: 0.113
-
New testing for lung cancer screening. Oncology (Williston Park). 2012 Feb; 26(2):176-82.
Score: 0.076
-
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov; 5(4):237-42.
Score: 0.043
-
Screening and early detection efforts in lung cancer. Cancer. 2015 May 01; 121(9):1347-56.
Score: 0.023